New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, China charts how to deal with dementia during the COVID-19 pandemic, starting with a helpful global and regional overview.
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, explores if digital twins are game-changers in clinical research and clinical care.
Dr. Josef Penninger led an international team from the University of British Columbia to pioneer a trial drug that could stop infection in the early stages of COVID-19.
Prof Dr Freimut Schliess, Director, Science & Innovation at Profil GmbH, sheds light on how Clinical Contract Research Organisations are building the digital bridge connecting clinical research and clinical care.
Numbers have reached record highs with over 870,000 clinical trial participants involved in research studies supported by the National Institute for Health Research (NIHR) over the last year.
Naoko Tanese from New York University School of Medicine outlines their work around Huntington’s disease (HD) and new targets for therapeutic intervention
Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University provides an overview of the professional development courses offered at the unit
Managing Director of The Cancer Drug Development Forum, Prof. H. Zwierzina reveals his opinions on the current and future challenges of personalised cancer therapy, including the need for biomarkers.
Life Science leaders from across the UK have welcomed a new agreement that will make it easier for life-changing clinical trials and medicines research and development to take place across different parts of the UK
